Medtronic reported 4.1% organic revenue growth and 6.2% adjusted EPS growth. See why we upgraded MDT stock to 'Buy' with a ...

Medtronic announced today that it brought its Affera mapping and ablation system into clinical use for the first time in ...

Medtronic posted a strong profit for Q3 of fiscal year 2025, though shares were down as its cardiac ablation product success was offset by weaker sales from its medical-surgical business.

Medtronic was the latest company to outline a bright future for pulsed field ablation (PFA). Physicians have embraced PFA over radiofrequency and cryoablation to treat atrial fibrillation since ...

The Global Radiofrequency Ablation Device Market is expected to grow at 9.35% CAGR from 2025 to 2032. The latest Research report published by Coherent Market Insights with the title "An Increase ...